Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!
- PMID: 27001566
- PMCID: PMC5321044
- DOI: 10.1200/JCO.2015.65.0879
Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet!
Comment in
-
Reply to A. Korfel et al.J Clin Oncol. 2016 May 20;34(15):1830-1. doi: 10.1200/JCO.2016.66.4722. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001567 No abstract available.
-
Reply to A. Korfel et al.J Clin Oncol. 2016 May 20;34(15):1831-2. doi: 10.1200/JCO.2016.66.4730. Epub 2016 Mar 21. J Clin Oncol. 2016. PMID: 27001575 No abstract available.
Comment on
-
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial.J Clin Oncol. 2015 Nov 20;33(33):3903-10. doi: 10.1200/JCO.2015.61.1236. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282634 Clinical Trial.
References
-
- Ferreri AJ, Donadoni G, Cabras MG, et al. High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic b-cell lymphoma and secondary CNS involvement: Final results of a multicenter phase II trial. J Clin Oncol. 2015;33:3903–3910. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
